FDA approves sNDA for Xeljanz

Share this article:

Pfizer said yesterday that FDA approved a supplemental New Drug Application (sNDA) to update the label of RA pill Xeljanz to include radiographic data from two Phase-III studies, ORAL Scan and ORAL Start.

The updated US label will now include the radiographic response data from ORAL Scan (Study IV) at 6 months and ORAL Start (Study VI) at 6 and 12 months. These studies evaluated the effect of the drug on the progression of structural joint damage.

The ORAL Start study showed that Xeljanz was superior to methotrexate by a statistically significant margin in inhibiting progression of structural joint damage, while the ORAL Scan study showed Xeljanz reduced progression of structural joint damage more than placebo. 

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.